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Abstract
Background: Diarrhea is a severe complication in HIV-1-infected patients with Trans-activator of transcription (HIV-1
Tat) protein being recognized as a major underlying cause. Beside its direct enterotoxic effects, Tat protein has
been recently shown to affect enteric glial cell (EGC) activity. EGCs regulate intestinal inflammatory responses by
secreting pro-inflammatory molecules; nonetheless, they might also release immune-regulatory factors, as
palmytoilethanolamide (PEA), which exerts anti-inflammatory effects by activating PPARα receptors. We aimed at
clarifying whether EGCs are involved in HIV-1 Tat-induced diarrhea and if PEA exerts antidiarrheal activity.
Methods: Diarrhea was induced by intracolonic administration of HIV-1 Tat protein in rats at day 1. PEA alone or in
the presence of peroxisome proliferator-activated receptor (PPAR) antagonists was given intraperitoneally from day
2 to day 7. S100B, iNOS, NF-kappaB, TLR4 and GFAP expression were evaluated in submucosal plexi, while S100B
and NO levels were measured in EGC submucosal plexi lysates, respectively. To verify whether PEA effects were
PPARα-mediated, PPARα−/− mice were also used. After 7 days from diarrhea induction, endogenous PEA levels were
measured in submucosal plexi homogenates deriving from rats and PPARα−/− mice.
Results: HIV-1 Tat protein induced rapid onset diarrhea alongside with a significant activation of EGCs. Tat
administration significantly increased all hallmarks of neuroinflammation by triggering TLR4 and NF-kappaB
activation and S100B and iNOS expression. Endogenous PEA levels were increased following HIV-1 Tat exposure in
both wildtype and knockout animals. In PPARα−/− mice, PEA displayed no effects. In wildtype rats, PEA, via PPARα-
dependent mechanism, resulted in a significant antidiarrheal activity in parallel with marked reduction of EGC-
sustained neuroinflammation.
Conclusions: EGCs mediate HIV-1 Tat-induced diarrhea by sustaining the intestinal neuroinflammatory response.
These effects are regulated by PEA through a selective PPARα-dependent mechanism. PEA might be considered as
an adjuvant therapy in HIV-1-induced diarrhea.
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Background
The use of combined anti-retroviral therapy against hu-
man immunodeficiency virus-type 1 (HIV-1) infection
has dramatically improved the survival and prognosis of
patients affected by the acquired immunodeficiency syn-
drome (AIDS) [1]. However, chronic diarrhea is reported
in up to 30% of HIV-1-infected patients and significantly
contributes to AIDS morbidity [2, 3].
Many of the pathogenic effects of HIV-1 in the gut are
caused by the HIV-1 trans-activating factor protein (Tat), a
viral protein of 86 aminoacids, which is essential to viral
replication [4]. HIV-1 Tat targets enterocytes and induces
the expression of many genes regulating cells’ survival and
growth; but it also affects immune and inflammatory re-
sponses, altering the intracellular calcium concentration, in-
ducing epithelial cell apoptosis, and ultimately causing
secretory diarrhea [5, 6]. The intestinal epithelial mucosa
has been considered for years as the key target in HIV-1
Tat-related enterotoxicity; however, the enteric nervous sys-
tem (ENS) is now emerging to be also involved [7, 8].
Within the ENS, enteric glial cells (EGCs), together with
neurons, cooperate to finely regulate secretion, motility, and
blood flow, as well as immune responses [9–11]. EGCs ex-
press Toll-like receptors (TLRs), and there is mounting evi-
dence suggesting that they actively participate to the
homeostatic immune control of the gut [12]. EGCs are able
to secrete pro-inflammatory mediators, interleukins, and
enteroglial-released factors [13–15], but they also release a
number of protective mediators that sustain epithelial bar-
rier functions [16–18]. Among EGC-derived factors, S100B,
a specific glial Ca+2/Zn+2-binding protein, and nitric oxide
(NO) deriving from the inducible isoform of nitric oxide
synthase (iNOS) expressed by EGCs play a central role dur-
ing immune-inflammatory responses [14, 19, 20]. We re-
cently demonstrated that glial cells participate to HIV-1
Tat-induced intestinal and neurological pathogenesis [21],
but the possibility to pharmacologically modulate Tat-
induced secretory diarrhea by inhibiting EGC activation has
not been explored yet.
Palmitoylethanolamide (PEA), an endogenous, on-de-
mand released N-Acylethanolamide [22–24], exerts im-
munoregulatory functions targeting EGC activation in
ulcerative colitis, with a consistent protection of colonic
epithelial mucosa [25]. Different studies have shown that
the pharmacological activity of PEA depends on its
capacity to selectively bind peroxisome proliferator-
activated receptor-α (PPARα), a member of a nuclear
hormone receptor superfamily of ligand-activated tran-
scription factor [24]. The involvement of and the ability
of PEA to protect against HIV-1 Tat-induced diarrhea
have never been investigated.
The aims of the present study were to investigate the
involvement of EGCs in a rat model of diarrhea induced
by the intracolonic administration of HIV-1 Tat, to
characterize the mediators secreted by EGCs activation,
and to evaluate the protective effect of PEA, its site, and
mechanisms of action, respectively.
Methods
Animals and experimental design
Eight-week-old Wistar male rats (Harlan Laboratories,
Udine, Italy) and 6-week-old PPARα−/− mice (Taconic,
Germantown, New York, USA) were used for experiments.
All procedures were approved by La Sapienza University’s
Ethics Committee. Animal care was in compliance with the
IASP and European Community (EC L358/1 18/12/86)
guidelines on the use and protection of animals in experi-
mental research. Rats were randomly divided into the fol-
lowing groups (n = 8 each): non-diarrhea, vehicle group;
HIV-1 Tat protein-induced diarrhea group; HIV-1 Tat
protein-induced diarrhea group receiving daily PEA 2 and
10 mg/Kg, respectively; HIV-1 Tat protein-induced diarrhea
group receiving daily PEA (10 mg/Kg) and selective PPARα
antagonist MK866 (10 mg/Kg) and selective PPARγ antag-
onist GW9662 (1 mg/Kg), respectively; HIV-1 Tat protein-
induced diarrhea group receiving 0.03% w/v lidocaine; bisa-
codyl group (20 mg/Kg) as internal control in some experi-
ments. Analogously, PPARα−/− mice were randomly divided
into the following groups (n = 8 each): non-diarrhea, vehicle
group; HIV-1 Tat protein-induced diarrhea group; HIV-1
Tat protein-induced diarrhea group receiving daily PEA 50
and 100 mg/Kg, respectively; HIV-1 Tat protein-induced
diarrhea group receiving 0.03% w/v lidocaine; bisacodyl
group (20 mg/Kg) as internal control in some experiments.
Diarrhea was experimentally induced by intracolonic
administration of HIV-1 Tat protein (130 ng/Kg) at day
1. HIV-1 Tat was dissolved in pyrogen-free distillated
water and a volume of 400 μl or 40 μl of a 100 ng/ml so-
lution of HIV-1 Tat was injected into the lumen of the
rat and PPARα−/− mice colon (3–4 cm proximal to anus)
by using a 24-gauge catheter, respectively. PEA alone, or
combined with PPARs antagonists, was given intraperi-
toneally from day 1 to day 7.
In a subset of experiments, lidocaine hydrochloride
monohydrate (Sigma-Aldrich, Milan, Italy, 0.03% w/v) dis-
solved in sterile, pyrogen-free distilled water, was given in a
single dose through intracolonic administration at day 1
concomitantly with HIV-1 Tat. In another set of experi-
ments, bisacodyl was administrated orally as aqueous
solution at day 1 and served as positive internal control. De-
pending upon the experimental plan, at day 7, animals were
euthanatized and colon was isolated to perform macro-
scopic, histochemical, and biochemical analyses as de-
scribed below.
Evaluation of diarrhea
Depending upon the experimental protocol, animals were
separated in subgroups and placed separately in cages lined
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with filter paper to evaluate diarrhea severity. The individ-
ual cages were inspected every 2 h for 16 h, from day 1 to
day 7 after HIV 1-Tat intracolonic administration, for the
presence of characteristic wet diarrhoeal droppings. Daily
defecation frequency and number of unformed water fecal
pellets of each animal were assessed and compared with
the score from the vehicle group. The data were expressed
as a daily mean score (16 h) of diarrhoeal dropping number
and total number of fecal pellets/wet spots for defecation
frequency within 7 days from diarrhea induction. Evalu-
ation of accumulation of intracolonic fluid was performed
using the enteropooling technique according to previously
described method [26]. Briefly, enteropooling is defined as
the intraluminal accumulation of fluid into the small intes-
tine and corresponds with the fluid already located in the
lumen and excreted from the blood. According to the ex-
perimental plan, the entire small intestine and colon of rats
and PPARα−/− mice were isolated, taken care to avoid tissue
rupture and loss of fluid, by removing the mesentery and
connective tissue. To normalize the data, fluid accumula-
tion was expressed as follows:
W 1−W 2ð Þ=W 2  10−6
where W1 is the weight of the intestine after excision
and W2 is the weight of the intestine after expulsion of
its content. Water content was measured and compared
with the score from vehicle group.
Tissue preparation
To isolate submucosal plexi from animals at day 7 after
diarrhea induction, we performed a slightly modified
method than previously described procedure by Cirillo et
al. [14]. Following dissection, colonic segments (approxi-
mately 2-cm long) were collected and placed in a cold ox-
ygenated sterile Krebs solution containing (in mM) 117
NaCl, 4.7 KCl, 1.2 MgCl2 6 H2O, 1.2 NaH2PO4, 25
NaHCO3, 2.5 CaCl2 2 H2O, and 11 glucose under carbo-
gen (5% CO2, 95% O2) atmosphere equilibrated at pH 7.4.
The tissue was longitudinally cut along the mesenteric
border, and the submucosal plexus was carefully separated
from the mucosal and the muscle layers by microdissec-
tion. After removal, submucosal plexi were processed for
biochemical and immunofluorescence assays.
Protein extraction and western blot analysis
Proteins were extracted from submucosal plexi deriving
from rats and PPARα−/− mice at day 7 after diarrhea in-
duction. The tissue was homogenized in ice-cold hypo-
tonic lysis buffer to obtain cytosolic extracts and
underwent electrophoresis through a polyacrilamide
minigel. Proteins were transferred into nitrocellulose
membrane that were saturated with non-fat dry milk
and then incubated with either mouse anti-S100B (Neo-
Marker, Milan, Italy), mouse anti-iNOS, rabbit anti-
GFAP, rabbit anti-TLR4, and mouse anti-β-actin (all
Santa Cruz Biotechnology, Santa Cruz, California, USA).
Membranes were then incubated with the specific sec-
ondary antibodies conjugated to horseradish peroxidase
(Dako, Milan, Italy). Immune complexes were revealed
by enhanced chemiluminescence detection reagents
(Amersham Biosciences, Milan, Italy). Blots were ana-
lyzed by scanning densitometry (GS-700 imaging densi-
tometer; Bio-Rad). Results were expressed as OD
(arbitrary units; mm2) and normalized on the expression
of the housekeeping protein β-actin.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed to detect NF-kappaB activation in
submucosal plexi obtained from rats and PPARα−/− mice at
day 7 after diarrhea induction. Double-stranded oligonucle-
otides containing the NF-kappaB recognition sequence for
rats (5–CAACGG CAGGGGAATCTCCCTCTCCTT-3)
and mice (5-TCAGAGGGGACTTTCCGAGAGG-3) were
end-labeled with 32Pγ-ATP. Nuclear extracts were incu-
bated for 15 min with radiolabeled oligonucleotides (2.5–
5.0 × 104 cpm) in 20 ml reaction buffer containing 2 mg
poly dI-dC, 10 mM Tris–HCl (pH 7.5), 100 mM NaCl,
1 mM ethylenediaminetetraacetic acid, 1 mM dl-dithiothre-
itol, 1 mg/ml bovine serum albumin, and 10% (v/v) glycerol.
Nuclear protein-oligonucleotide complexes were resolved
by electrophoresis on a 6% non-denaturing polyacrylamide
gel in 1 Tris Borate ethylenediaminetetraacetic acid buffer
at 150 V for 2 h at 4 °C. The gel was dried and autoradio-
graphed with an intensifying screen at − 80 °C for 20 h.
Subsequently, the relative bands were quantified by densito-
metric scanning with Versadoc (Bio-Rad Laboratories) and
a computer program (Quantity One Software, Bio-Rad La-
boratories). 32P-γ-ATP was from Amersham (Milan, Italy).
Poly dI-dC was from Boehringer-Mannheim (Milan, Italy).
Oligonucleotide synthesis was performed to our specifica-
tions by Tib Molbiol (Boehringer-Mannheim).
NO quantification
NO was measured as nitrite (NO2
−) accumulation in sub-
mucosal plexi homogenates deriving from rats and
PPARα−/− mice at day 7 after diarrhea induction, by a
spectrophotometer assay based on the Griess reaction.
Briefly, Griess reagent (1% sulphanilamide, 0.1% naphthy-
lethylenediamine in phosphoric acid) was added to an
equal volume of supernatant, and the absorbance was
measured at 550 nm. Nitrite concentration (nM) was thus
determined using a standard curve of sodium nitrite.
Enzyme-linked immunosorbent assay for S100B
Enzyme-linked immunosorbent assay (ELISA) for S100B
(Biovendor R&D, Brno, Czech Republic) was carried out
on submucosal plexi lysates obtained from rats and
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PPARα−/− mice at day 7 after diarrhea induction, accord-
ing to the manufacturer’s protocol. Absorbance was
measured on a microtiter plate reader. S100B level was
determined using standard curves method.
Immunofluorescence analysis
Additional experiments were performed using specific iso-
type antibody controls (Abcam, Cambridge, UK), at the
same concentration as the primary antibodies. Tissues were
then incubated in the dark with the proper secondary anti-
body: fluorescein isothiocyanate-conjugated anti-rabbit or
Texas Red-conjugated anti-mouse, respectively (both Jack-
son ImmunoResearch Laboratories, West Grove, PA,
USA). Tissues were analyzed with a microscope (Nikon
Eclipse 80i), and images were captured by a high-resolution
digital camera (Nikon Digital Sight DS-U1).
Measurement of PEA in rats and mice EGCs
Tissue content of endogenous PEA was measured in
submucosal plexi homogenates deriving from both rats
and PPARα−/− mice at day 7 after diarrhea induction.
Following isolation of lipidic fraction by tissue homoge-
nates, intracellular PEA concentrations (pmol) were nor-
malized per milligram of extracted lipid fraction and
were analyzed by liquid chromatography coupled to tan-
dem mass spectrometry (LC-MS/MS) using a 325-MS
LC/MS Triple Quadrupole Mass Spectrometer (Agilent
Technologies Italia, Cernusco s/N, Italy) according to lit-
erature [27].
Statistical analysis
Results were expressed as mean ± SEM of n experiments.
A statistical analysis was performed using parametric
one-way analysis of variance (ANOVA), and multiple
comparisons were performed by Bonferroni’s post hoc
test; p values < 0.05 were considered significant.
Results
Intracolonic administration of HIV-1 Tat induces diarrhea
in rats and stimulates the release of endogenous PEA
Intracolonic administration of HIV-1 Tat-induced acute
diarrhea, starting from day 1 and lasting up to 7 days
post treatment; the severity of which was significantly
improved by PEA, in a concentration-dependent fashion
and in PPARα-dependent manner (Fig. 1). Interestingly,
the antidiarrheal effect of PEA appeared to be specific-
ally related to HIV-1 Tat administration since PEA treat-
ment failed to significantly inhibit bisacodyl-induced
diarrhea, even at the highest dose (Additional file 1).
In order to provide a rational for the antidiarrheal ef-
fect of PEA, we measured its intracellular content in
submucosal plexi after 7 days from the induction of the
diarrhea. We found that HIV-1 Tat significantly in-
creased the levels of endogenous PEA and that this
increase was significantly inhibited by lidocaine (+ 147
and − 50% vs. vehicle group and HIV-1 Tat group, re-
spectively; all p < 0.01; Fig. 2); in rats receiving bisacodyl,
the tissue content of PEA was unaffected, likely suggest-
ing that it is dependent by the activation of EGCs.
HIV-1 Tat induces an inflammatory response through EGC
activation that is inhibited by PEA
Administration of HIV-1 Tat induced a significant acti-
vation of NF-κΒ and resulted in an increased expression
of GFAP, S100B, TLR4, and iNOS in rat submucosal
plexi (Fig. 3, all p < 0.001 vs. vehicle group); significantly,
the S100B and nitrite levels were also increased.
PEA treatment significantly reduced HIV-1 Tat-induced
NF-κB activation, in a dose-dependent manner (− 42 and
− 58%, p < 0.01 and p < 0.001); similarly, the activation of
EGCs was inhibited by PEA, with the expression of GFAP
(− 35 and − 69%), S100B (− 29 and − 65%), TLR4 (− 31
and − 70%), iNOS (− 35 and 74%), and the levels of S100B
(− 27 and − 64%) and nitrite (− 30 and − 64%) being all
significantly reduced (p < 0.01 and p < 0.001; at 2 and
10 mg/kg, respectively; Fig. 3). The ability of PEA to re-
duce HIV-1 Tat-induced EGC activation was significantly
inhibited by MK866, but not by GW9662, suggesting that
its effect was mediated by PPAR-α rather than by PPAR-γ.
PEA failed to significantly affect the release of EGC-
derived mediators in rats with bisacodyl-induced diarrhea
(Fig. 3), and this finding suggests that its effect specifically
targets HIV-1 Tat-induced diarrhea by acting on EGC-
related activation.
Further supporting the involvement of EGCs, a signifi-
cantly higher S100B/iNOS expression was observed in
the submucosal plexi preparation of HIV-1 Tat-treated
rats, compared to vehicle group (+ 310 and + 260%, re-
spectively, p < 0.001) (Fig. 4). Treatment with PEA (2–
10 mg/kg) reduced the expression of both markers, in a
concentration-dependent manner (− 28 and − 50%, − 26
and − 40% for S100B and iNOS, respectively; p < 0.01
and p < 0.001 vs. HIV-1 Tat; Fig. 4). Similar to what was
reported above, the effect of PEA was inhibited by the
presence of the PPARα-, but not PPARγ-antagonist,
while bisacodyl administration failed to modify S100B/
iNOS expression (Fig. 4).
PEA treatment failed to improve HIV-1 Tat-induced diarrhea
and EGC-associated neuroinflammation in PPARα−/− mice
Intracolonic administration of HIV-1 Tat protein in-
duced acute diarrhea in PPARα−/− mice, similar to what
was observed in a subset of wild mice (data not shown)
and in rats (Additional file 2); the diarrhea was associ-
ated with the increased activation of NF-kappaB of sub-
mucosal enteric glial cells and the upregulation of
S100B/iNOS expression (Fig. 5). In line with the results
obtained with the PPARα antagonist, treatment with
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PEA, even at highest doses, failed to significantly im-
prove the diarrhea in PPARα−/− mice and had no effect
on the activation of EGCs induced by HIV-1 Tat (Fig. 5).
Bisacodyl treatment was able to induce the diarrhea
in PPARα−/− mice, but was unaffected by the adminis-
tration of PEA (Fig. 5). Bisacodyl failed to modify the
tissue content of endogenous PEA which was, con-
versely, significantly increased by HIV-1 Tat adminis-
tration and inhibited by lidocaine (+ 250% vs. vehicle
group, and − 55% vs. HIV-1 Tat group, respectively; all
p < 0.01; Fig. 5).
Discussion
Secretory diarrhea is a common clinical issue ob-
served in nearly 60–80% of HIV-1 patients, and it is
considerably widespread in third-world countries
[28]. So far, HIV-1 Tat protein has been identified as
the main responsible for the damage of intestinal
mucosal, by promoting pro-oxidant and pro-
apoptotic-mediated disruption of colonic epithelial
cells and consequently the intestinal barrier integrity
[5, 29]. More recently, it has been described that
HIV-1 Tat protein has an additional effect on the
Fig. 1 Palmitoylethanolamide (PEA) improves diarrheal hallmarks in rats via PPARα activation. Intracolonic administration of HIV-1 Tat protein
(130 ng/Kg) resulted in a significant increase of a daily defecation frequency, b average daily number of wet spots, and c fluid accumulation
within 7 days from diarrhea induction. Administration of PEA significantly improved diarrhea in a concentration-dependent manner (at 2 and
10 mg/kg, respectively); the antidiarrheal activity of PEA was significantly inhibited in the presence of PPARα antagonist (MK866), whereas PPARγ
antagonist (GW9662) had no effect. The results are expressed as mean ± SEM of n = 5 experiments. ***p < 0.001 vs. vehicle group; °°p < 0.01 and °°
°p < 0.001 vs. HIV-1 Tat group
Fig. 2 HIV-1 Tat administration increases endogenous PEA levels in submucosal plexi EGCs. As a consequence of HIV-1 Tat intracolonic administration,
a marked increase of PEA produced in rat submucosal plexi was observed in comparison with vehicle group. Lidocaine (0.03% w/v) counteracted this
HIV-1 Tat-induced effect, while bisacodyl treatment did not induce any significant changes in PEA levels. The results are expressed as mean ± SEM of
n = 5 experiments. **p < 0.01 vs. vehicle group; °°p < 0.01 vs. HIV-1 Tat group
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nervous part of the gut, the ENS [7, 21, 30]. This
direct action on the nervous system, which regulates
many intestinal functions, causes abnormalities in
neuronal excitability that, together with the release
of pro-inflammatory cytokines in the intestinal mi-
lieu, contributes to gut dysfunction described in HIV
patients [7].
Our results demonstrate that, beside its effect on
enteric neurons, HIV-1 Tat protein also targets EGCs
and mediates the overexpression of specific glial
markers, as S100B and GFAP, in colonic submucosal
plexus with a parallel increase in the expression of
iNOS protein and pro-inflammatory signaling mole-
cules (i.e., NO).
These final events occur via activation of the NF-
kappaB-mediated cascade and TLR4 activation, two mo-
lecular pathways that are linked to each other during
EGC activation [25].
The ability of the ENS to modulate virus-induced diar-
rhea was first reported by Lundgren et al., who showed
that the inhibition of enteric nerves excitability was able
to significantly inhibit the diarrhea induced by rotavirus
[31]. Accordingly, we showed that lidocaine challenge
was able to dampen symptoms and biochemical markers
indicative for secretory diarrhea, further supporting the
role of the ENS, as a whole, in mediating HIV-1 Tat-
induced diarrhea. We here show that enteric glia cells
take part in mediating the diarrhea induced by viral
Fig. 3 PEA inhibits HIV-1 Tat-induced inflammatory response in rat submucosal plexus-EGCs. HIV-1 Tat (130 ng/Kg) administration induced a significant
increase of NF-κB activation and GFAP, S100B, TLR, and iNOS protein expression, as well as S100B and NO2− levels in submucosal plexi deriving from rats on
day 7 after diarrhea induction. All HIV-1 Tat-mediated effects were inhibited by PEA (2–10 mg/kg) in a dose- and PPARα-dependent manner. Bisacodyl
(20 mg/kg) did not show any significant effect. EMSA and immunoblot analysis showed, respectively, a NF-kappaB activation complex bands, b their
densitometric quantification (OD = optical density in mm2), c representative immunoreactive bands of analyzed proteins, and d–g their respective
densitometric quantification (normalized against the expression of the housekeeping protein β-actin; OD = optical densitometry in mm2). h, i Levels
of S100B and NO2
− in submucosal plexi homogenates. The results are expressed as mean ± SEM of n = 5 experiments ***p < 0.001 vs. vehicle group;
°°p < 0.01 and °°°p < 0.001 vs. HIV-1 Tat group
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toxin and that their modulation is able to reduce HIV-1
Tat diarrheagenic effects by inhibiting the overexpres-
sion of S100B and iNOS and of the TLR4/NF-kappaB
axis, respectively.
Furthermore, supporting the role of EGCs and their
activation in HIV-1 Tat diarrhea, we also observed that
when the secretory diarrhea was induced by a non-
immunological stimulus (i.e., bisacodyl), no significant
changes in glial network and markers were noticed.
Furthermore, we evaluated whether PEA was able to
decrease glial activation and to improve the diarrhea, re-
spectively. PEA has been recently showed to improve co-
lonic inflammation through EGCs/TLR4-dependent
PPARα activation [25]. Here, we demonstrated that PEA
administration significantly and dose-dependently coun-
teracted all diarrheal hallmarks in rodents, as shown by
the decrease of stool frequency and weight, and by the
rescue of water losses in colonic lumen.
According to our previous reports in human and animal
models of intestinal inflammation, we also showed that
the anti-diarrheal effect of PEA was selectively mediated
by PPARα receptor activation [25, 32]. In fact, PPARα, but
not PPARγ antagonist, significantly inhibited PEA effects,
with this being further confirmed in a transgenic PPARα
knockout model. Though HIV-1 Tat administration in
these mice-induced secretory diarrhea, the treatment with
PEA, even at high doses, did not evoke any anti-diarrheal
effect, likely because the site of action was not expressed.
However, it has to be noted that PPARα receptor sites are
expressed by EGCs, as well as by enteric neurons, sup-
porting that the anti-diarrheagenic effects of PEA are
more likely to be the result of its synergistic effects on
both neurons and glial cells.
According to our previous results, obtained in an ex-
perimental model of colitis [25], PEA was able to
dampen EGC activation and the consequent overexpres-
sion of S100B and iNOS protein in the submucosal
plexus isolated from colon. Moreover, we found that
PEA, through the selective PPARα involvement, blocked
the TLR4/NF-kappaB activation in the submucosal
plexus of rats with HIV-1 Tat-induced diarrhea. These
effects caused a decreased activation of EGCs with the
reduction of S100B, GFAP, iNOS, and NO expression in
the cell milieu. In PPARα−/− mice, PEA failed to prevent
HIV-1 Tat-induced EGC activation, further confirming
that these effects are mediated by PPARα receptors.
Since its discovery, PEA has been believed to be an en-
dogenous cannabinoid-like lipid able to suppress inflam-
matory responses in vitro [33]; moreover, PEA has been
described to reduce gastrointestinal motility in mice
model of colitis [34]. Also, during intestinal inflammation,
PEA level increases, most probably as a protective re-
sponse to mucosal damage [35]. The observation that
PEA levels are higher in colonic mucosa of patients with
ulcerative colitis and in experimental models of colitis
strengths, the hypothesis that this endogenous compound
Fig. 4 PEA reduces S100B/iNOS expression in submucosal plexi of HIV-1 Tat-treated rat. Immunofluorescence analysis showing that HIV-1 Tat (130 ng/Kg)
induced a marked increase of S100B and iNOS expression in submucosal plexi that was reduced by PEA through a PPARα-dependent mechanism. Bisacodyl
(20 mg/kg) administration failed to significantly affect S100B/iNOS co-expression. a The panel shows S100B (red) and iNOS (green) immunoreactivity and b
their respective quantification (open and filled bars indicate S100B and iNOS expression, respectively). The results are expressed as mean ± SEM of n= 5
experiments. ***p< 0.001 vs. vehicle group; °°p< 0.01 and °°°p< 0.001 vs. HIV-1 Tat group. Scale bar = 20 μm
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may act as “on-demand modulator” of inflammatory pro-
cesses in the gut [36]. Very interestingly, we found that in
our models of HIV-1 Tat-induced diarrhea, the levels of
endogenous PEA are significantly increased, while in the
non-immunologic model of diarrhea obtained via bisaco-
dyl administration, they remained unaltered. The fact that
the endogenous level of PEA was significantly reduced by
lidocaine indicates that, at least in our experimental
Fig. 5 PEA fails to counteract submucosal plexus-EGC activation induced by HIV-1 Tat in PPARα−/− mice. EMSA analysis showed marked upregulation
of NF-kappaB in submucosal plexi at day 7 following HIV-1 Tat administration, compared to vehicle group. PEA was ineffective to reduce NF-kappaB
activation in PPARα−/− mice, while bisacodyl (20 mg/kg) did not induce NF-kappaB upregulation. a Representative NF-kappaB activation complex
bands and b their densitometric quantification (OD = optical density in mm2). HIV-1 Tat significantly increased GFAP, S100B, TLR4, and iNOS protein
expression and S100B and NO2
− levels in submucosal plexi isolated from PPARα−/− mice in the same experimental conditions. Again, HIV-1
Tat-mediated effects were unaffected by PEA, while bisacodyl did not induce any change in the above investigated parameters. c
Representative immunoreactive bands of analyzed proteins, d–g their respective densitometric quantification (normalized against the
expression of the housekeeping protein β-actin; OD = optical densitometry in mm2) and h, i S100B and NO2− levels. Immunofluorescence
analysis showed an increased S100B/iNOS co-expression in submucosal plexus-EGCs at day 7 after HIV-1 Tat administration, vs. vehicle
group. As expected, PEA was unable to counteract HIV-1 Tat activity and bisacodyl did not induce any S100B/iNOS upregulation. l S100B
(red) and iNOS (green) immunoreactivity with m the respective quantification of S100B (open bars) and iNOS (filled bars) expression in
the submucosal plexi. n HIV-1 Tat caused a marked increase of endogenous PEA content in submucosal plexi vs. vehicle group. Lidocaine
inhibited HIV-1 Tat activity, whereas bisacodyl did not produce any alteration in endogenous PEA production. The results are expressed as
mean ± SEM of n = 5 experiments. **p < 0.01 and ***p < 0.001 vs. vehicle group; °°p < 0.01 and °°°p < 0.001 vs. HIV-1 Tat group.
Scale bar = 100 μm
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conditions, PEA acts specifically by following the immune
stimulus (HIV-1 Tat protein), behaving like a regulative
ALIAmide and such action is intimately modulated by the
ENS, and at least partly mediated by EGC activity.
Conclusions
Although we cannot definitely rule out the role of enteric
neuron dysfunction in mediating these effects, our results
indicate that EGCs play a role in HIV-1 Tat-induced diar-
rhea and highlight the importance of these cells in regulat-
ing immune/inflammatory response featuring intestinal
disturbance occurring in AIDS infection. We also demon-
strated that PEA, by targeting HIV-1 Tat-induced neu-
roinflammatory responses, significantly modulates the
diarrhea and that this occurs through the selective PPARα
involvement. If confirmed by clinical trials in humans, our
findings suggest that PEA, given its low cost and toxico-
logical profile [37], might be regarded as promising tool
that may integrate the current therapeutic approaches for
treating a high-morbidity condition like diarrhea in HIV-
infected patients.
Additional files
Additional file 1: PEA failed to inhibit bisacodyl-induced diarrhea in rats.
Bisacodyl (20 mg/kg) caused a significant increase of (a) daily defecation
frequency, (b) average daily number of wet spots, and (c) fluid accumula-
tion within 7 days from diarrhea induction, vs. vehicle group. PEA (2–10–
50 mg/kg) resulted ineffective to exert any anti-diarrheal activity. The re-
sults are expressed as mean ± SEM of n = 5 experiments. ***p < 0.001 vs.
vehicle group. (TIFF 1347 kb)
Additional file 2: PEA failed to improve diarrhea course in PPARα−/−
mice. HIV-1 Tat (130 ng/Kg)-induced diarrhea in PPARα−/− mice, increas-
ing (a) daily defecation frequency, (b) average daily number of wet spots,
and (c) fluid accumulation within 7 days from diarrhea induction, vs. ve-
hicle group. PEA (50–100 mg/kg) did not show any significant effect even
at highest doses. The results are expressed as mean ± SEM of n = 5 exper-
iments. ***p < 0.001 vs. vehicle group. (TIFF 580 kb)
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